Development of a proposed biosimilar product based on the demonstration of physicochemical, pharmacologic and clinical similarity to filgrastim.
Bibliographic record
Abstract
e13528 Background: Biosimilar development involves extensive analytical testing to ensure comparability to the reference medicinal product to support the demonstration of similarity in terms of clinical efficacy and safety. We report physicochemical, functional and clinical characterization of the proposed biosimilar, Apo-Filgrastim to the reference product Neupogen. Methods: A variety of orthogonal methods was applied to analyze primary and higher order structures, purity, and biological activity. Methods included spectroscopic and chromatographic methods and a cell based potency assay. An extensive clinical program was also conducted. Three single-dose Phase I studies were performed with Apo-Filgrastim and Neupogen in healthy volunteers over a dose range of ~ 1- 5 µg/kg. A multiple-dose study at 5 µg/kg/day was also performed. Absolute Neutrophil Count (ANC) was the primary PD endpoint used as surrogate marker for efficacy. CD34+ count was assessed as a secondary efficacy measure under multiple dose conditions. A Phase III, non-comparative study was conducted in 120 breast cancer patients to assess efficacy, safety and immunogenicity of Apo-Filgrastim. Results: Apo-Filgrastim has the same primary and higher order structure as Neupogen as seen by peptide mapping and 2D-NMR. Purity of Apo-Filgrastim averaged 99.8%, vs. 99.7% for Neupogen, using RP-HPLC. Potency of Apo-Filgrastim was equivalent to Neupogen as demonstrated in a cell-based bioassay. Clinical results demonstrated PK similarity between Apo-Filgrastim and Neupogen, such that for all studies, the 90% CI of the primary PK endpoint parameters AUC and Cmax was contained within a pre-defined acceptance limit of 80-125%. PD similarity was also demonstrated with the 95% CI of primary ANC PD endpoint parameters AUC and Cmax falling within pre-defined limits of 80-125%. Clinical efficacy and patient safety data for Apo-Filgrastim were consistent with those reported for Neupogen. Conclusions: In vitro analysis demonstrated finger-print-like similarity, and the clinical program demonstrated that there are no clinically meaningful differences between Apo-Filgrastim and Neupogen.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.012 | 0.009 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".